From the Department of Radiology (J.G.N., K.M.K., S.H.C., W.H.L., R.-E.Y., J.-H.K., T.J.Y., C.-H.S.), Seoul National University Hospital, Seoul, Korea.
From the Department of Radiology (J.G.N., K.M.K., S.H.C., W.H.L., R.-E.Y., J.-H.K., T.J.Y., C.-H.S.), Seoul National University Hospital, Seoul, Korea
AJNR Am J Neuroradiol. 2017 Dec;38(12):2243-2250. doi: 10.3174/ajnr.A5417. Epub 2017 Oct 26.
Glioblastoma is the most common primary brain malignancy and differentiation of true progression from pseudoprogression is clinically important. Our purpose was to compare the diagnostic performance of dynamic contrast-enhanced pharmacokinetic parameters using the fixed T1 and measured T1 on differentiating true from pseudoprogression of glioblastoma after chemoradiation with temozolomide.
This retrospective study included 37 patients with histopathologically confirmed glioblastoma with new enhancing lesions after temozolomide chemoradiation defined as true progression ( = 15) or pseudoprogression ( = 22). Dynamic contrast-enhanced pharmacokinetic parameters, including the volume transfer constant, the rate transfer constant, the blood plasma volume per unit volume, and the extravascular extracellular space per unit volume, were calculated by using both the fixed T1 of 1000 ms and measured T1 by using the multiple flip-angle method. Intra- and interobserver reproducibility was assessed by using the intraclass correlation coefficient. Dynamic contrast-enhanced pharmacokinetic parameters were compared between the 2 groups by using univariate and multivariate analysis. The diagnostic performance was evaluated by receiver operating characteristic analysis and leave-one-out cross validation.
The intraclass correlation coefficients of all the parameters from both T1 values were fair to excellent (0.689-0.999). The volume transfer constant and rate transfer constant from the fixed T1 were significantly higher in patients with true progression ( = .048 and .010, respectively). Multivariate analysis revealed that the rate transfer constant from the fixed T1 was the only independent variable (OR, 1.77 × 10) and showed substantial diagnostic power on receiver operating characteristic analysis (area under the curve, 0.752; = .002). The sensitivity and specificity on leave-one-out cross validation were 73.3% (11/15) and 59.1% (13/20), respectively.
The dynamic contrast-enhanced parameter of rate transfer constant from the fixed T1 acted as a preferable marker to differentiate true progression from pseudoprogression.
胶质母细胞瘤是最常见的原发性脑恶性肿瘤,区分真性进展与假性进展在临床上非常重要。本研究旨在比较使用固定 T1 值和测量 T1 值获得的动态对比增强药代动力学参数在替莫唑胺放化疗后鉴别胶质母细胞瘤真性进展与假性进展中的诊断性能。
本回顾性研究纳入了 37 例经组织病理学证实的新出现强化病灶的胶质母细胞瘤患者,这些患者在替莫唑胺放化疗后被定义为真性进展(n = 15)或假性进展(n = 22)。使用固定 T1 值(1000ms)和多翻转角法测量 T1 值,计算容积转移常数、速率转移常数、血容量分数和细胞外间隙分数。通过组内相关系数评估观察者内和观察者间的可重复性。使用单变量和多变量分析比较两组间的动态对比增强药代动力学参数。通过受试者工作特征分析和留一交叉验证评估诊断性能。
两种 T1 值的所有参数的组内相关系数均为中等至极好(0.689-0.999)。真性进展患者的固定 T1 值的容积转移常数和速率转移常数明显较高(分别为 P =.048 和.010)。多变量分析显示,固定 T1 值的速率转移常数是唯一的独立变量(OR,1.77×10),在受试者工作特征分析中具有较大的诊断能力(曲线下面积,0.752; P =.002)。留一交叉验证的敏感性和特异性分别为 73.3%(11/15)和 59.1%(13/20)。
固定 T1 值的动态对比增强药代动力学参数可作为区分真性进展与假性进展的更优标志物。